Information:
Fel:
ID
34413
Beskrivning
Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01753375
Länk
https://clinicaltrials.gov/show/NCT01753375
Nyckelord
Versioner (1)
- 2019-01-17 2019-01-17 -
Rättsinnehavare
GSK group of companies
Uppladdad den
17 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Multiple Sclerosis NCT01753375
Eligibility Multiple Sclerosis NCT01753375
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Sclerosis NCT01753375
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
age between 18-55 years
boolean
ID.2
Item
confirmed multiple sclerosis diagnosis according to mcdonald criteria
boolean
ID.3
Item
stable neurological functioning for at least one month prior to study entry
boolean
ID.4
Item
expanded disability scale score (edss) less than <_4.0
boolean
ID.5
Item
must have had one clinical attack in past two years and at least one new silent t2 or gadolinium-enhancing lesion on mri within the past one year.
boolean
ID.6
Item
willing to participate for the entire 52-week period
boolean
ID.7
Item
pregnant or nursing.
boolean
ID.8
Item
connective tissue disease (sle, sjogren's disease)
boolean
ID.9
Item
endocrine disease (hyperthyroidism, hyperparathyroidism)
boolean
ID.10
Item
any medical condition predisposing to hypercalcaemia, nephrolithiasis or renal insufficiency
boolean